Sp1297
ATTENTION ON MASH: EXPLORING THE ROLE OF METABOLIC DYSFUNCTION IN A CHRONIC LIVER DISEASE
Date
May 21, 2024
Presenter
Houston Methodist Hospital
Tracks
Related Products
Obesity and Advanced Liver Disease
SOCIETY: DDW
ALT, FIBROSCAN VCTE, AND FIBROSCAN CAP AS PREDICTIVE MARKERS OF RESMETIROM BIOPSY RESPONSE
INTRODUCTION. MAESTRO-NASH (NCT03900429) is an ongoing 54-month, randomized, double-blind, placebo-controlled Phase 3 trial evaluating the efficacy of resmetirom in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and fibrosis…
